DK1343013T3 - Fremgangsmåder til screening af forbindelser der modulerer apoptose, forbindelser der er identificeret ved fremgangsmåderne, og anvendelse af forbindelserne som terapeutiske midler - Google Patents

Fremgangsmåder til screening af forbindelser der modulerer apoptose, forbindelser der er identificeret ved fremgangsmåderne, og anvendelse af forbindelserne som terapeutiske midler

Info

Publication number
DK1343013T3
DK1343013T3 DK02290578T DK02290578T DK1343013T3 DK 1343013 T3 DK1343013 T3 DK 1343013T3 DK 02290578 T DK02290578 T DK 02290578T DK 02290578 T DK02290578 T DK 02290578T DK 1343013 T3 DK1343013 T3 DK 1343013T3
Authority
DK
Denmark
Prior art keywords
compounds
methods
apoptotic
screening
therapeutic agents
Prior art date
Application number
DK02290578T
Other languages
English (en)
Inventor
Alphonse Garcia
Xavier Cayla
Angelita Rebollo
Veronica Ayllon
Aarne Fleischer
Original Assignee
Pasteur Institut
Consejo Superior Investigacion
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Consejo Superior Investigacion, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK1343013T3 publication Critical patent/DK1343013T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
DK02290578T 2002-03-07 2002-03-07 Fremgangsmåder til screening af forbindelser der modulerer apoptose, forbindelser der er identificeret ved fremgangsmåderne, og anvendelse af forbindelserne som terapeutiske midler DK1343013T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02290578A EP1343013B1 (en) 2002-03-07 2002-03-07 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents.

Publications (1)

Publication Number Publication Date
DK1343013T3 true DK1343013T3 (da) 2006-08-21

Family

ID=27741248

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02290578T DK1343013T3 (da) 2002-03-07 2002-03-07 Fremgangsmåder til screening af forbindelser der modulerer apoptose, forbindelser der er identificeret ved fremgangsmåderne, og anvendelse af forbindelserne som terapeutiske midler

Country Status (13)

Country Link
US (2) US7217534B2 (da)
EP (2) EP1343013B1 (da)
JP (1) JP4414231B2 (da)
CN (1) CN100529759C (da)
AT (1) ATE324589T1 (da)
AU (1) AU2003226678B2 (da)
CA (1) CA2478042A1 (da)
CY (1) CY1105513T1 (da)
DE (1) DE60210919T2 (da)
DK (1) DK1343013T3 (da)
ES (1) ES2262765T3 (da)
PT (1) PT1343013E (da)
WO (1) WO2003075015A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2881430B1 (fr) * 2005-02-01 2010-10-22 Servier Lab Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations
US7897401B2 (en) * 2005-11-29 2011-03-01 University Of Maryland, College Park Control of apoptosis by controlling the propensity of ceramide channel formation
EP2132570A4 (en) * 2007-03-20 2010-04-21 Inst Medical W & E Hall SCREENING METHOD
PT2194783T (pt) 2007-08-10 2017-08-14 Vm Discovery Inc Composições e métodos para moduladores da apoptose
EP3535441A4 (en) * 2016-11-03 2020-06-17 Cell Microsystems, Inc. AUTOMATED COLLECTION OF A SPECIFIC NUMBER OF CELLS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3855409A (en) * 1970-04-01 1974-12-17 Schmid Lab Method for treating hypercholesterolemia
EP1140112B1 (en) * 1998-12-21 2005-03-09 Inkeysa, S.A. Etherlysophospholipids for the treatment of chronic inflammatory diseases
JP2003506071A (ja) * 1999-05-28 2003-02-18 アポプトシス テクノロジー，アイエヌシー． アポトーシスを制御する化合物および方法ならびにアポトーシスを制御する化合物を製造およびスクリーニングする方法
US20020068271A1 (en) * 1999-12-27 2002-06-06 Amnon Altman Methods for identifying agents capable of modulating protein kinase C theta (PKC0) activity
AU2002252015A1 (en) * 2001-02-16 2002-09-04 Arbor Vita Corporation Pdz domain interactions and lipid rafts

Also Published As

Publication number Publication date
JP4414231B2 (ja) 2010-02-10
WO2003075015A3 (en) 2003-12-24
ATE324589T1 (de) 2006-05-15
CA2478042A1 (en) 2003-09-12
PT1343013E (pt) 2006-09-29
US7217534B2 (en) 2007-05-15
WO2003075015A2 (en) 2003-09-12
US20060040331A1 (en) 2006-02-23
EP1481250A2 (en) 2004-12-01
CY1105513T1 (el) 2010-04-28
CN1650169A (zh) 2005-08-03
JP2005518813A (ja) 2005-06-30
AU2003226678A1 (en) 2003-09-16
ES2262765T3 (es) 2006-12-01
EP1343013B1 (en) 2006-04-26
CN100529759C (zh) 2009-08-19
DE60210919T2 (de) 2007-05-10
AU2003226678B2 (en) 2009-12-10
US20070184435A1 (en) 2007-08-09
EP1343013A1 (en) 2003-09-10
DE60210919D1 (de) 2006-06-01

Similar Documents

Publication Publication Date Title
DK1891020T3 (da) Fremgangsmåder til fremstilling af azoxystrobin ved brug af DABCO som katalysator og hidtil ukendte mellemprodukter, der anvendes i fremgangsmåderne
DK1807504T3 (da) Serumfrit cellekulturmedium til celler fra pattedyr
NZ603648A (en) Methods of purifying polypeptides
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
DK1661278T3 (da) Forbedret uplink drift ved blöd overlevering
DK1545574T3 (da) Fremgangsmåde til rensning af polypeptider ved simuleret moving-bed-chromatografi
NO20034944D0 (no) Re-aktiverte T-celler for adoptiv immunoterapi
IL164531A (en) Immunomodulatory compounds for modulating mammalian cd34+ or cd133+ hematopoietic stem cells differentiation
WO2007022515A3 (en) Stem cell derived factors for treating pathologic conditions
BRPI0412667A (pt) sìntese regiosseletiva de cci - 779
FR2893627B1 (fr) Procede pour l'ajustement du pouvoir calorifique superieur du gaz dans la chaine du gnl.
NO20065084L (no) Interferon-alfa polypeptider og konjugater
DE602004028343D1 (de) Verkleidungsmaterial mit kontrollierter porosität für bauplatten
DE60303898D1 (de) Apparat zum Betreiben von Gasturbinen
DK1343013T3 (da) Fremgangsmåder til screening af forbindelser der modulerer apoptose, forbindelser der er identificeret ved fremgangsmåderne, og anvendelse af forbindelserne som terapeutiske midler
CL2008003587A1 (es) Polipeptido que comprende un epitope inductor de la muerte celular; metodo de produccion de anticuerpos; metodo de identificacion de un compuesto candidato para inducir la muerte de las celulas t activadas. (divisional solicitud n° 1082-05)
DE60224275D1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
NZ551828A (en) A method of cell isolating a homogenous population of mammary stem cells using specific cell surface marker proteins
DE60209150D1 (de) Dichtungsystem für elektrolysezelle
IS7154A (is) Bv8 kjarnsýrur og fjölpeptíð með mítósu-valdandi verkun
GB0220553D0 (en) Method andapparatus for determining the viability of eggs
DE60306810D1 (de) Polyethylen-giesszusammensetzung zum herstellen von grossbehältern
EA200602261A1 (ru) Подвижная плита
DE19840936B4 (de) Anordnung zum mehrkanaligen Schneiden und Ritzen von Materialien mittels Laserstrahlen
IL158913A0 (en) Methods for predicting the activities of cellular constituents